Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 895-905

  Moran, Diarmuld M ^a,b   Maki, Carl G ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; F ACTIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; VINCULIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; DRUG ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS FIBER;

ACTINS; CELL LINE, TUMOR; CELL MOVEMENT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOSKELETON; FOCAL ADHESIONS; HUMANS; IMIDAZOLES; NEOPLASM INVASIVENESS; PIPERAZINES; PSEUDOPODIA; STRESS FIBERS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950807948     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1220     Document Type: Article

References (35)

1. Giono L, Manfredi J. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006;209:13-20.
2. Harris S, Levne A. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-2908
3. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
4. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-3459
5. Levav-Cohen Y, Haupt S, Haupt Y. Mdm2 in growth signaling and cancer. Growth Factors 2005;23:183-192
6. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003;1:993-1000.
7. Vassilev L, Vu B, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848
8. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-1893
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
10. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol 2004;265:23-32.
11. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science 2003;302:1704-1709
12. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003;3:362-374
13. Sahal E, Marshall C. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003;5:711-719
14. Alexandrova A, Ivanov A, Chumakov P, Kopnin B, Vaslllev J. Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization. Oncogene 2000;19:5826-5830
15. Gadéa G, Lapasset L, Gauthier-Rouvière C, Roux P. Regulation of Cdc42-medlated morphological effects: a novel function for p53. EMBO J 2002;21:2373-2382
16. Guo F, Gao Y, Wang L, Zheng Y. p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities. J Biol Chem 2003;278:14414-14419
17. Guo F, Zheng Y. Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion. Oncogene 2004;23:5577-5585
18. Gadea G, de Toledo M, Anguille C, Roux P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol 2007;178:23-30.
19. Sahai E. Mechanisms of cancer cell invasion. Curr Opin Genet Dev 2005;15:87-96.
20. Van Maerken T, Speleman F, Vermeulen J, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 2006;66:9646-9655
21. Seechiero P, Corallini F, Gonelli A, et al. Antlangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 2007;100:61-69
22. Moskovits N, Kalinkovich A, Bar J, Lapidot T, Oren M. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/ CXCL12 expression in stromal fibroblasts. Cancer Res 2006;66: 10671-10676
23. Dow L, Kauffman J, Caddy J, et al. The tumour-suppressor Scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge. Oncogene 2007;26: 2272-2282
24. Kuo J, Wang W, Yao C, Wu P, Chen R. The tumor suppressor DAPK inhibits cell motility by blocking the integrin-mediated polarity pathway. J Cell Biol 2006;172:619-631
25. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-695
26. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-456
27. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56
28. Taichman RS, Cooper C, Keller ET, Plenta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837
29. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 2007;98:1652-1658
30. Kedrin D, van Rheenen J, Hernandez L, Condeells J, Segall J. Cell motility and cytoskeletal regulation in invasion and metastasis. J Mammary Gland Biol Neoplasia 2007;12:143-152
31. Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004;64:7022-7029
32. Goswami S, Sahai E, Wyckoff JB, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/ epidermal growth factor paracrine loop. Cancer Res 2005;65:5278-5283
33. Qian LW, Mizumoto K, Maehara N, et al. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett 2003;190:105-112
34. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002;62:7328-7334
35. Sun YX, Schneider A, Jung Y, et al. Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005;20:318-329